CLEC10A and teratocarcinoma: HML-2 expression in humans was first clearly linked to teratocarcinoma, where HML-2 RNA, protein and non-infectious virions are produced from diseased cells [11,12,13,14] and patients exhibit immune responses against expressed HML-2 antigens [15,16,17].